Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report)’s share price was up 3.8% during mid-day trading on Wednesday . The company traded as high as $0.41 and last traded at $0.41. Approximately 11,166 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 20,761 shares. The stock had previously closed at $0.39.
Panbela Therapeutics Trading Up 3.8 %
The company has a 50 day simple moving average of $0.37 and a 200 day simple moving average of $0.35. The stock has a market cap of $1.97 million, a P/E ratio of -0.01 and a beta of 1.40.
Panbela Therapeutics Company Profile
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Recommended Stories
- Five stocks we like better than Panbela Therapeutics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- P/E Ratio Calculation: How to Assess Stocks
- Alphabet’s Officially In A Bear Market—Time To Buy?
- How to Calculate Inflation Rate
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.